Impact of comorbidity and relative dose intensity on outcomes in diffuse large B-cell lymphoma patients treated with R-C
- PDF / 1,048,794 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 84 Downloads / 171 Views
ORIGINAL ARTICLE – CLINICAL ONCOLOGY
Impact of comorbidity and relative dose intensity on outcomes in diffuse large B‑cell lymphoma patients treated with R‑CHOP Masakazu Yamamoto1,2 · Ikuko Suzuki2 · Kouji Saitou3 · Riko Tsumanuma4 · Shuhei Okuyama4 · Hiroaki Kumagai4 · Eijiro Omoto4 · Shinji Satoh2 · Katsushi Tajima4 Received: 27 December 2019 / Accepted: 30 May 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Background Comorbidity and relative dose intensity (RDI) have been associated with survival in diffuse large B-cell lymphoma (DLBCL) patients, but both relationships remain unaddressed in the same patients. Methods A retrospective review of consecutive DLBCL patients treated from January 2010 to October 2018 was performed. Data for the clinical characteristics of the patients, including the Charlson Comorbidity Index (CCI) and RDI, on their outcomes were evaluated. Results A total of 211 patients with a median age of 72 years (range 19–90 years) were analyzed. CCI ≥ 2 was associated with poor event-free survival (EFS) and overall survival (OS). RDI
Data Loading...
